Categories AlphaGraphs, Earnings, Health Care
Everything you need to know about Biogen’s (BIIB) Q1 2023 earnings
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported lower earnings, on an adjusted basis, and revenues for the first quarter of 2023.
Total revenue declined 3% year-over-year to $2.46 billion. For the full year of 2023, the company expects revenues to decline in the mid-single digit percentage and projects adjusted earnings per share in the range of $15.00 to 16.00.
Net income attributable to Biogen Inc. was $387.9 million or $2.67 per share in Q1, compared to $303.8 million or $2.06 per share last year. Adjusted earnings declined 6% to $3.40 per share.
Prior Performance
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Important takeaways from Broadcom’s (AVGO) Q4 2023 earnings
Semiconductor company Broadcom, Inc. (NASDAQ: AVGO) ended fiscal 2023 on a positive note, delivering strong results for the fourth quarter. In the new fiscal year, the company’s focus will be
Here’s what Signet Jewelers (SIG) expects for the holiday season and beyond
Shares of Signet Jewelers Limited (NYSE: SIG) were down over 2% on Friday. The stock has gained 40% year-to-date and 27% over the past three months. The jewelry retailer saw
DOCU Earnings: DocuSign Q3 2024 revenue up 9%; profit beats estimates
eSignature service provider DocuSign, Inc. (NASDAQ: DOCU) reported higher revenues and better-than-expected adjusted earnings for the third quarter of 2024. The company also provided guidance for the fourth quarter and
